FineMark National Bank & Trust Sells 292 Shares of Thermo Fisher Scientific Inc. $TMO

FineMark National Bank & Trust lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,849 shares of the medical research company’s stock after selling 292 shares during the quarter. FineMark National Bank & Trust’s holdings in Thermo Fisher Scientific were worth $9,264,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. J.W. Cole Advisors Inc. lifted its position in shares of Thermo Fisher Scientific by 113.5% during the 1st quarter. J.W. Cole Advisors Inc. now owns 3,828 shares of the medical research company’s stock worth $1,905,000 after purchasing an additional 2,035 shares during the last quarter. GW&K Investment Management LLC boosted its stake in Thermo Fisher Scientific by 1.5% during the 1st quarter. GW&K Investment Management LLC now owns 38,310 shares of the medical research company’s stock valued at $19,063,000 after purchasing an additional 583 shares during the period. Finally, Clifford Swan Investment Counsel LLC increased its position in Thermo Fisher Scientific by 12.9% in the 1st quarter. Clifford Swan Investment Counsel LLC now owns 509 shares of the medical research company’s stock worth $253,000 after buying an additional 58 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 51,845 shares of company stock valued at $28,956,952. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.6%

Shares of TMO opened at $576.01 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a market cap of $216.41 billion, a PE ratio of 33.28, a PEG ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The stock has a 50 day simple moving average of $531.35 and a 200-day simple moving average of $470.43.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TMO shares. Evercore ISI increased their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a report on Tuesday, October 28th. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.